CARLSBAD, Calif., Feb. 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. , today announced the pricing of 2,086,957 shares of outstanding common stock being offered by certain existing stockholders to the public at the price of $25.50 per share. Genoptix, Inc. will not receive any proceeds from the sale. The offer is expected to close on March 5, 2008.
The offering is being made through an underwriting syndicate led by Lehman Brothers, Inc. acting as sole book-running manager. Banc of America Securities LLC and UBS Investment Bank are acting as joint lead managers with Cowen and Company, LLC as co-manager. The selling stockholders have granted the underwriters a 30-day option to purchase up to 313,043 additional shares of common stock.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 28, 2008. This offering is being made by the existing stockholders solely by means of written prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, by contacting Lehman Brothers, Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, fax: 631-254-7140, or e-mail: qiana.smith@broadridge.com, or at the Securities and Exchange Commission’s website: http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.
CONTACT: Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc.,
+1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz,
Principal, Mentus, +1-858-455-5500, ext. 215, jschultz@mentus.com, for
Genoptix, Inc.
